Rheumatology
Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.
Recent Discussions
What is your approach to management of recurrent Kikuchi-Fujimoto Disease?
My experience with recurrent Kikuchi–Fujimoto disease (KFD) is limited, as I have not managed many recurrences; however, this is the general framework I use in practice. At the time of a recurrence, I first reassess the diagnosis and consider potential mimics—particularly infection, lymphoma, and ev...
In patients with relapsing polychondritis with suboptimal response to NSAIDs and prednisone, what are strategies you use for flare treatment?
It depends on multiple variables, including organ involvement, disease activity, and associated manifestations. I would be happy to discuss it further if you would like.
How do you approach management of chronic cough in patients with ILD?
By the time an individual presents with ILD and cough, and fibrotic therapy has started, there’s almost no use for increasing the dose to treat cough instead of a neural modulator such as gabapentin, and if cough is interrupting sleep, low-dose narcotics. The spinoff is that narcotics may reduce dia...
How do you weigh the risks of re-treatment with infliximab in a patient who has been off it for over a year?
To answer this question, we first need to go back in time. Treatment with infliximab has been known to elicit the formation of antibodies against infliximab. The presence of these antibodies has been associated with infusion reactions in 7-19 % of patients and may also shorten the duration of the ef...
Are there specific conventional DMARDs and/or biologics that are contraindicated in patients with alpha-gal allergy?
Here is a Q&A from AAAAI (American Academy of Allergy, Asthma and Immunology) addressing this question for etanercept and other monoclonal antibodies that are manufactured in cell lines that glycosylate with alpha-gal. The author concludes, "The risk is not zero, but likely very low".
What are some practical tips for eliciting an accurate history of Raynaud's phenomenon in patients being assessed for CTD?
I use this approach. I first ask patients if they feel generally sensitive to the cold. All patients with Raynaud's should respond yes to this, but this is not specific, as there are many cold-sensitive patients who don't have Raynaud's. I will then ask if their fingers turn any colors in response t...
How do you approach a child with recurrent parotitis who has had negative serum testing for Sjogren's and IgG4 related disease?
Minor salivary gland biopsy is pretty random and subjective; finding >50 lymphocytes per set field is not that specific/helpful. I would think a parotid gland biopsy and extensive work-up (TB, HIV, sarcoid, lymphoma, etc.) is in order.
How frequently do you monitor CT scans, PFTs, and TTEs in patients with ILA or mild ILD?
Typically, I want my patients with ILD to be seen in clinic every 3-4 months, but of course, that depends a great deal on individual circumstances (e.g., disease severity, what we're doing for their disease, etc.). My typical approach is to have my patients perform spiro, DLCO, and 6MWT Q 3-4 months...
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
I usually start with a high dose at 60 mg daily for a few weeks, then add DMARDs like MTX.
Do you find trabecular bone score (TBS) useful in patients with a history of ankylosing spondylitis when screening for vertebral fracture risk?
Yes, the ankylosing spondylitis population is a group that could benefit from the evaluation of TBS. DXA-based spine bone mineral density is artificially elevated in the setting of ankylosing spondylitis (due to osteosclerotic artifact from underlying disease), and therefore, spine bone density is a...